Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis (TMC278LA)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Bill and Melinda Gates Foundation
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Information provided by (Responsible Party):
PATH
ClinicalTrials.gov Identifier:
NCT02165202
First received: May 21, 2014
Last updated: March 14, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: October 2017
  Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)